Drug intelligence / Profile preview

NWRD06

Development stage: Phase 2
Lead developer: Newish Technology
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NWRD06 is a DNA plasmid therapeutic vaccine targeting glypican-3 (GPC3), developed by Newish Technology (Beijing). It is designed as an immunotherapy for GPC3-positive hepatocellular carcinoma, aiming to stimulate the immune system to recognize and attack cancer cells expressing GPC3. The drug functions as a GPC3 inhibitor and is currently in Phase 1 clinical trials to evaluate its safety and immunogenicity in patients with hepatocellular carcinoma following radical resection[1][3][4].

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on NWRD06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWRD06.

Explore the full profile